Compass Therapeutics, Inc.

The momentum for this stock is not very good. Compass Therapeutics, Inc. is not a good value stock. Compass Therapeutics, Inc. is not a good growth stock. Compass Therapeutics, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Compass Therapeutics, Inc..

News

Panagora Asset Management Inc. Buys Shares of 68,268 Compass Therapeutics, Inc. (NASDAQ:CMPX)

Zolmax Panagora Asset Management Inc. purchased a new position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) in the second quarter, Holdings Channel.com reports. The institutional...\n more…

Compass Therapeutics to Participate in Upcoming Investor Events

Globe Newswire BOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...\n more…

Compass Therapeutics files $300M mixed securities shelf

SeekingAlpha.com: All News Learn about a recent filing for a $300M mixed securities shelf in this informative article by a financial writer.\n more…

Compass Therapeutics files $300M mixed securities shelf

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Reviewing Compass Therapeutics (NASDAQ:CMPX) & Voyager Therapeutics (NASDAQ:VYGR)

Ticker Report Compass Therapeutics (NASDAQ:CMPX - Get Free Report) and Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will...\n more…

Compass Therapeutics, Inc. (NASDAQ:CMPX) Sees Significant Decline in Short Interest

Ticker Report Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) was the recipient of a large decline in short interest in the month of July. As of July 31st, there was short interest totalling 1,890,000...\n more…